- Home
- TEVA vs CCEP Comparison
TEVA vs CCEP Comparison
Compare TEVA & CCEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TEVA | CCEP |
|---|---|---|
| Founded | 1901 | 1986 |
| Country | Israel | United Kingdom |
| Employees | 32842 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.1B | 44.0B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | TEVA | CCEP |
|---|---|---|
| Price | $31.15 | $105.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $38.63 | ★ $104.33 |
| AVG Volume (30 Days) | ★ 4.2M | 1.8M |
| Earning Date | 04-29-2026 | 02-17-2026 |
| Dividend Yield | N/A | ★ 2.48% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.86 |
| Revenue Next Year | $2.97 | $3.79 |
| P/E Ratio | $28.19 | ★ $20.93 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.99 | $84.66 |
| 52 Week High | $37.35 | $110.90 |
Technical Indicators
Market Signals| Indicator | TEVA | CCEP |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 60.68 |
| Support Level | $30.59 | $89.51 |
| Resistance Level | $32.40 | $108.47 |
| Average True Range (ATR) | 0.92 | 1.97 |
| MACD | -0.15 | -0.36 |
| Stochastic Oscillator | 34.13 | 78.88 |
Price Performance
Historical ComparisonAbout TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
About CCEP Coca-Cola Europacific Partners plc
CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe, Australasia, and Southeast Asia. In 2025, CCEP sold 3.9 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume.TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.